BIIB Stock Recent News

BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.

Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday.

Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is generating positive longer-term clinical data. Biogen's pipeline includes potential revenue contributors in Alzheimer's, Parkinson's, and kidney disease therapies, pain therapeutics and MS.

Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

DAVIS, Calif.--(BUSINESS WIRE)--The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools.

A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.

Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.